Cyclacel Pharmaceuticals Stock Performance
| CYCC Stock | USD 2.00 0.02 1.01% |
On a scale of 0 to 100, Cyclacel Pharmaceuticals holds a performance score of 2. The firm shows a Beta (market volatility) of -1.05, which signifies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Cyclacel Pharmaceuticals are expected to decrease slowly. On the other hand, during market turmoil, Cyclacel Pharmaceuticals is expected to outperform it slightly. Please check Cyclacel Pharmaceuticals' treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to make a quick decision on whether Cyclacel Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cyclacel Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain fundamental indicators, Cyclacel Pharmaceuticals exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:15 | Dividend Date 2020-04-15 | Last Split Date 2023-12-18 |
1 | CYCC Stock Earnings Cyclacel Pharmaceuticals Misses EPS for Q4 2023 | 03/20/2024 |
2 | Insider Trading | 04/03/2024 |
3 | Cyclacel Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future | 04/25/2024 |
4 | NKTR, IMNM and MAIA are among premarket gainers | 04/30/2024 |
5 | Cyclacel Pharmaceuticals Announces Closing of 8.0 Million Private PlacementPriced At-The-Market Under NASDAQ Rules | 05/02/2024 |
6 | Cyclacel Pharmaceuticals Price Target Lowered to 11.00 at Roth Mkm - Defense World | 05/07/2024 |
7 | Earnings call Cyclacel Pharmaceuticals reports Q1 2024 results | 05/15/2024 |
8 | Acquisition by Barker Sam L of 5200 shares of Cyclacel Pharmaceuticals at 4.7 subject to Rule 16b-3 | 05/17/2024 |
9 | Acquisition by Banham John Michael Middlecott of 5200 shares of Cyclacel Pharmaceuticals at 4.7 subject to Rule 16b-3 | 05/31/2024 |
10 | All You Need to Know About Cyclacel Pharmaceuticals Rating Upgrade to Buy | 06/06/2024 |
| Begin Period Cash Flow | 18.3 M | |
| Free Cash Flow | -16.1 M |
Cyclacel |
Cyclacel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 248.00 in Cyclacel Pharmaceuticals on March 12, 2024 and sell it today you would lose (48.00) from holding Cyclacel Pharmaceuticals or give up 19.35% of portfolio value over 90 days. Cyclacel Pharmaceuticals is currently generating 0.3154% in daily expected returns and assumes 12.1163% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Cyclacel, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cyclacel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclacel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyclacel Pharmaceuticals, and traders can use it to determine the average amount a Cyclacel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.026
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CYCC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.12 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.32 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Cyclacel Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclacel Pharmaceuticals by adding it to a well-diversified portfolio.
Cyclacel Pharmaceuticals Fundamentals Growth
Cyclacel Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclacel Pharmaceuticals, and Cyclacel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclacel Stock performance.
| Return On Equity | -4.96 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (150.17) % | ||||
| Current Valuation | 149.52 K | ||||
| Shares Outstanding | 1.46 M | ||||
| Price To Earning | (0.40) X | ||||
| Price To Book | 3.82 X | ||||
| Price To Sales | 5.52 X | ||||
| Revenue | 420 K | ||||
| Gross Profit | (455 K) | ||||
| EBITDA | (30.27 M) | ||||
| Net Income | (22.55 M) | ||||
| Cash And Equivalents | 29.08 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 37 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.38 X | ||||
| Book Value Per Share | (1.67) X | ||||
| Cash Flow From Operations | (16.11 M) | ||||
| Earnings Per Share | (22.02) X | ||||
| Market Capitalization | 2.93 M | ||||
| Total Asset | 8.8 M | ||||
| Retained Earnings | (428.28 M) | ||||
| Working Capital | (717 K) | ||||
| Current Asset | 24.57 M | ||||
| Current Liabilities | 5.75 M | ||||
About Cyclacel Pharmaceuticals Performance
To evaluate Cyclacel Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cyclacel Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cyclacel Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cyclacel Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Cyclacel's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -74 K | -70.3 K | |
| Return On Tangible Assets | (2.56) | (2.43) | |
| Return On Capital Employed | (47.05) | (44.70) | |
| Return On Assets | (2.56) | (2.43) | |
| Return On Equity | (37.16) | (35.30) |
Things to note about Cyclacel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cyclacel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyclacel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclacel Pharmaceuticals had very high historical volatility over the last 90 days | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K). | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from zacks.com: All You Need to Know About Cyclacel Pharmaceuticals Rating Upgrade to Buy |
- Analyzing Cyclacel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclacel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cyclacel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclacel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclacel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclacel Pharmaceuticals' stock. These opinions can provide insight into Cyclacel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |